Chardan Capital Markets has recently initiated Mind Medicine (MindMed) Inc (MNMD) stock to Buy rating, as announced on December 20, 2024, according to Finviz. Earlier, on October 14, 2024, Leerink ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

周二，专注于迷幻药研究的生物科技公司Mind ...

Robert Barrow, the Chief Executive Officer of Mind Medicine (MindMed) Inc. (NASDAQ:MNMD), a $502 million market cap company that has delivered an impressive 108% return... Mark Sullivan ...

$60,000 of MIND MEDICINE INC. lobbying was just disclosed, from Q4 of 2024, in a new Lobbying Disclosure Act filing. This included lobbying on issues like: "Education and advocacy for novel brain ...

1 Day MNMD 9.91% DJIA 0.78% Russell 2K 0.40% Health Care/Life Sciences 1527.34% ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

Mind Medicine (MindMed) Inc. (NASDAQ:MNMD – Get Free Report) shares were down 8.5% on Friday following insider selling activity. The company traded as low as $6.98 and last traded at $6.98.

Check a company’s competitiveness in the job market with alternative data that tracks hiring, job openings, and more.

Leverage fair value analysis to evaluate the market value of stocks enabling more informed investment decisions.

Vancouver, Canada, Jan. 07, 2025 (GLOBE NEWSWIRE) -- Clearmind Medicine Inc. (Nasdaq: CMND), (FSE: CWY0) ("Clearmind" or the "Company"), a clinical-stage biotech company focused on discovery and ...